Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/2034
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMathur, Harshita-
dc.date.accessioned2008-09-18T08:44:56Z-
dc.date.available2008-09-18T08:44:56Z-
dc.date.issued2008-09-
dc.identifier.issn0971-5544-
dc.identifier.urihttp://hdl.handle.net/123456789/2034-
dc.description464-472en_US
dc.description.abstractAs the patents laws continually soar in dynamic transition, burning controversy that rages up is compulsory licensing under Section 92A of the Indian Patents Act enabling exportation of patented drugs. This dissertation is a research-based factual analysis of patents as a real barrier to the accessibility to drugs and the extent to which compulsory licensing remodels the situation, in reference to the latest legal development- Natco v Pfizer which has hauled the key provisions before the legal eye for severe scrutiny. This paper is an endeavour to analyse the issue of patents v patients in the light of a possible outcome of this potentially landmark case.en_US
dc.language.isoen_USen_US
dc.publisherCSIRen_US
dc.sourceJIPR Vol.13(5) [September 2008]en_US
dc.subjectPatentsen_US
dc.subjectTRIPSen_US
dc.subjectCompulsory licensingen_US
dc.subjectSection 92A, arbitrageen_US
dc.subjectR & Den_US
dc.titleCompulsory Licensing under Section 92A: Issues and Concernsen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.13(5) [September 2008]

Files in This Item:
File Description SizeFormat 
JIPR 13(5) 464-472.pdf116.8 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.